Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis

Michael R. Robinson, Chi Chao Chan, James C. Yang, Benjamin I. Rubin, Gerald J. Gracia, H. Nida Sen, Karl G. Csaky, Steven A. Rosenberg

Research output: Contribution to journalArticlepeer-review

Abstract

Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expressed on activated T cells. CTLA-4 blockade using a monoclonal antibody (mAb) in conjunction with tumor vaccines has improved tumor responses in animal models and enhanced numerous models of T cell-associated autoimmune diseases. Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti-CTLA-4 mAb therapy developed uveitis. This is the first report of autoimmune disease involving the eye in patients treated with anti-CTLA-4 mAb. This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.

Original languageEnglish (US)
Pages (from-to)478-479
Number of pages2
JournalJournal of Immunotherapy
Volume27
Issue number6
DOIs
StatePublished - 2004

Keywords

  • Autoimmunity
  • CTLA-4 antibody
  • Immunotherapy
  • Melanoma
  • Uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis'. Together they form a unique fingerprint.

Cite this